TY  - JOUR
AU  - Perez-Ruiz, Elisabeth
AU  - Minute, Luna
AU  - Otano, Itziar
AU  - Alvarez, Maite
AU  - Ochoa, Maria Carmen
AU  - Belsue, Virginia
AU  - de Andrea, Carlos
AU  - Rodriguez-Ruiz, Maria Esperanza
AU  - Perez-Gracia, Jose Luis
AU  - Marquez-Rodas, Ivan
AU  - Llacer, Casilda
AU  - Alvarez, Martina
AU  - de Luque, Vanesa
AU  - Molina, Carmen
AU  - Teijeira, Alvaro
AU  - Berraondo, Pedro
AU  - Melero, Ignacio
PY  - 2019
DO  - 10.1038/s41586-019-1162-y
UR  - http://hdl.handle.net/10668/13899
T2  - Nature
AB  - Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung cancer1-3. However, this comes at the cost of frequent, serious immune-related adverse events,...
LA  - en
KW  - Animals
KW  - Antibodies, Monoclonal
KW  - CD8-Positive T-Lymphocytes
KW  - CTLA-4 Antigen
KW  - Colitis
KW  - Colonic Neoplasms
KW  - Dextran Sulfate
KW  - Female
KW  - Graft vs Host Disease
KW  - Hepatitis
KW  - Humans
KW  - Immunotherapy
KW  - Ipilimumab
KW  - Male
KW  - Mice
KW  - Mice, Inbred C57BL
KW  - Nivolumab
KW  - Programmed Cell Death 1 Receptor
KW  - T-Lymphocytes
KW  - Tumor Necrosis Factor Inhibitors
KW  - Tumor Necrosis Factor-alpha
KW  - Xenograft Model Antitumor Assays
TI  - Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
TY  - research article
VL  - 569
ER  -